Loading...
•
Dec 31, 2024
DexCom Q4 2024 Earnings Report
DexCom reported solid revenue growth but faced margin compression.
Key Takeaways
DexCom achieved 8.00% YoY revenue growth in Q4 2024, reaching $1,113,500,000. However, net income declined significantly by 40.80% YoY due to increased operating expenses and margin pressure.
Revenue increased by 8.00% YoY, reaching $1,113,500,000.
International revenue growth of 17.00% outpaced U.S. revenue growth of 4.00%.
Net income declined 40.80% YoY, mainly due to higher expenses and margin compression.
GAAP operating margin dropped 400 bps YoY to 17.00%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
DexCom expects continued revenue growth in 2025, with strong international expansion and improving margins.
Positive Outlook
- Projected revenue growth of 14.00% to approximately $4,600,000,000.
- Non-GAAP gross profit margin expected between 64.00% and 65.00%.
- Non-GAAP operating margin projected at approximately 21.00%.
- Adjusted EBITDA margin expected to reach 30.00%.
- Expansion of reimbursement coverage in France for Dexcom ONE+ product.
Challenges Ahead
- Margin pressure persists despite projected improvements.
- U.S. revenue growth remains relatively slow at 4.00% in Q4 2024.
- Hardware revenue saw a significant decline of 49.00% YoY.
- Increasing operating expenses continue to impact profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...